

# The Effect of a Single Dose of Intravenous Ketamine on Review and Individual Participant Data Meta-Analysis

American Journal of Psychiatry

175, 150-158

DOI: [10.1176/appi.ajp.2017.17040472](https://doi.org/10.1176/appi.ajp.2017.17040472)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New medications for treatment-resistant depression: a brief review of recent developments. <i>CNS Spectrums</i> , 2017, 22, 39-48.	0.7	11
2	Sex differences in sub-anesthetic ketamine's antidepressant effects and abuse liability. <i>Current Opinion in Behavioral Sciences</i> , 2018, 23, 36-41.	2.0	16
3	Convergent Mechanisms Underlying Rapid Antidepressant Action. <i>CNS Drugs</i> , 2018, 32, 197-227.	2.7	127
4	Botulinum Toxin: Does it have a Place in the Management of Depression?. <i>CNS Drugs</i> , 2018, 32, 97-100.	2.7	1
5	Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. <i>American Journal of Psychiatry</i> , 2018, 175, 620-630.	4.0	496
6	Antisuicidal Effects of Ketamine: A Promising First Step. <i>American Journal of Psychiatry</i> , 2018, 175, 97-98.	4.0	4
7	Rapid-Acting Antidepressants: Mechanistic Insights and Future Directions. <i>Current Behavioral Neuroscience Reports</i> , 2018, 5, 36-47.	0.6	38
8	Preventing suicide: A multicausal model requires multimodal research and intervention. <i>Bipolar Disorders</i> , 2018, 20, 558-559.	1.1	3
10	Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. <i>F1000Research</i> , 2018, 7, 659.	0.8	152
11	On the safety of repeated ketamine infusions for the treatment of depression: Effects of sex and developmental periods. <i>Neurobiology of Stress</i> , 2018, 9, 166-175.	1.9	38
12	Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. <i>Journal of Psychiatric Research</i> , 2018, 106, 61-68.	1.5	119
13	No Sex-Specific Differences in the Acute Antidepressant Actions of (R)-Ketamine in an Inflammation Model. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 932-937.	1.0	24
14	Ketamine and depression. <i>British Journal of Anaesthesia</i> , 2018, 121, 1198-1202.	1.5	13
15	Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model. <i>Psychopharmacology</i> , 2018, 235, 3177-3185.	1.5	29
16	Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness. <i>Journal of Psychopharmacology</i> , 2018, 32, 1110-1117.	2.0	38
17	Recent Findings of the Comparative Efficacy and Tolerability of Antidepressants for Major Depressive Disorder: Do We Now Know What to Prescribe?. <i>CNS Drugs</i> , 2018, 32, 807-811.	2.7	1
18	Now is the time for (2R,6R)-hydroxynorketamine to be viewed independently from its parent drug. <i>Pharmacology Biochemistry and Behavior</i> , 2018, 175, 24-26.	1.3	5
19	AMPA Receptor Activation-independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine. <i>Biological Psychiatry</i> , 2018, 84, 591-600.	0.7	97

#	ARTICLE	IF	CITATIONS
20	The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?. , 2018, 190, 148-158.		160
21	Emerging evidence for antidepressant actions of anesthetic agents. Current Opinion in Anaesthesiology, 2018, 31, 439-445.	0.9	25
22	Ketamine: A Review for Clinicians. Focus (American Psychiatric Publishing), 2018, 16, 243-250.	0.4	7
23	Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting. Journal of Affective Disorders, 2018, 241, 103-109.	2.0	21
24	Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. International Journal of Environmental Research and Public Health, 2018, 15, 771.	1.2	80
25	Characterizing the course of suicidal ideation response to ketamine. Journal of Affective Disorders, 2018, 241, 86-93.	2.0	44
26	Rapid tranquillisation: the science and advice. BJ Psych Advances, 2018, 24, 346-358.	0.5	10
27	Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation. Journal of Psychopharmacology, 2018, 32, 601-640.	2.0	38
28	The influence of ketamine on drug discovery in depression. Drug Discovery Today, 2019, 24, 2033-2043.	3.2	57
29	The effects of ketamine on suicidality across various formulations and study settings. Mental Health Clinician, 2019, 9, 48-60.	0.5	35
30	Ketamine applications beyond anesthesia – A literature review. European Journal of Pharmacology, 2019, 860, 172547.	1.7	72
31	Differentially methylated regions in bipolar disorder and suicide. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 496-507.	1.1	19
32	Ketamine for Psychiatric Disorders. , 2019, , 149-160.		0
33	Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. Journal of Psychiatric Research, 2019, 110, 166-171.	1.5	41
34	Is suicidality a mental disorder? Applying DSM-5 guidelines for new diagnoses. Death Studies, 2019, 45, 1-13.	1.8	5
35	Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Translational Psychiatry, 2019, 9, 280.	2.4	133
36	The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial. Frontiers in Pharmacology, 2019, 10, 1325.	1.6	44
37	Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Molecular Psychiatry, 2019, 24, 1779-1786.	4.1	100

#	ARTICLE	IF	CITATIONS
38	Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-controlled study. <i>Neuropsychopharmacology</i> , 2019, 44, 2112-2118.	2.8	57
39	Effects of ketamine treatment on suicidal ideation: a qualitative study of patients' accounts following treatment for depression in a UK ketamine clinic. <i>BMJ Open</i> , 2019, 9, e029108.	0.8	18
40	(R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 665-674.	1.0	62
41	Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. <i>Neuropsychopharmacology</i> , 2019, 44, 1233-1238.	2.8	35
42	Ketamine for suicidal ideation treatment: Available evidence remains convincing. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 99, 1-2.	2.9	0
43	The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109668.	2.5	58
44	Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 613-627.	1.0	239
45	Critical appraisal of major depression with suicidal ideation. <i>Annals of General Psychiatry</i> , 2019, 18, 7.	1.2	66
46	Association of defecation disorders with suicidal ideation in young adult with chronic abdominal discomfort. <i>Journal of Affective Disorders</i> , 2019, 253, 308-311.	2.0	3
47	Rapid-acting antidepressants. <i>Advances in Pharmacology</i> , 2019, 86, 47-96.	1.2	49
48	Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 181, 53-59.	1.3	115
49	Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression. <i>American Journal of Psychiatry</i> , 2019, 176, 342-347.	4.0	15
50	Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function. <i>Molecular Psychiatry</i> , 2019, 24, 1816-1832.	4.1	103
51	Future of paediatric sedation: towards a unified goal of improving practice. <i>British Journal of Anaesthesia</i> , 2019, 122, 652-661.	1.5	12
52	The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF). <i>Journal of Psychiatric Research</i> , 2019, 113, 125-136.	1.5	64
53	Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD). <i>Journal of Affective Disorders</i> , 2019, 251, 162-169.	2.0	47
54	Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model. <i>Behavioural Brain Research</i> , 2019, 368, 111904.	1.2	35
55	Prognosis and improved outcomes in major depression: a review. <i>Translational Psychiatry</i> , 2019, 9, 127.	2.4	262

#	ARTICLE	IF	CITATIONS
56	Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. <i>Focus (American Psychiatric Publishing)</i> , 2019, 17, 55-65.	0.4	9
57	The Classification of Depression: Embracing Phenotypic Heterogeneity in the Era of the RDoC. , 2019, , 1-8.		0
58	Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: A meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2019, 250, 123-131.	2.0	32
59	Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder. <i>Journal of Psychopharmacology</i> , 2019, 33, 494-501.	2.0	35
60	Ketamine for Treatment-Resistant Mood Disorders. <i>Focus (American Psychiatric Publishing)</i> , 2019, 17, 8-12.	0.4	16
61	Treatments for the Prevention and Management of Suicide. <i>Annals of Internal Medicine</i> , 2019, 171, 334.	2.0	101
62	Assessment and Management of Patients at Risk for Suicide: Synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines. <i>Annals of Internal Medicine</i> , 2019, 171, 343.	2.0	39
63	Suicide Prevention Strategies for General Hospital and Psychiatric Inpatients: A Narrative Review. <i>Indian Journal of Psychological Medicine</i> , 2019, 41, 403-412.	0.6	15
66	Research on the pathophysiology, treatment, and prevention of suicide: practical and ethical issues. <i>BMC Psychiatry</i> , 2019, 19, 332.	1.1	24
67	Infusing Hope Into the Treatment of Suicidality: a Review of Ketamine's Effects on Suicidality. <i>Current Behavioral Neuroscience Reports</i> , 2019, 6, 166-176.	0.6	4
68	Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial. <i>BMC Psychiatry</i> , 2019, 19, 375.	1.1	21
69	Pharmacological Discrimination of Effects of MK801 on Thalamocortical, Mesothalamic, and Mesocortical Transmissions. <i>Biomolecules</i> , 2019, 9, 746.	1.8	25
70	Suicide Has Many Faces, So Does Ketamine: a Narrative Review on Ketamine's Antisuicidal Actions. <i>Current Psychiatry Reports</i> , 2019, 21, 132.	2.1	19
72	Suicide and suicide risk. <i>Nature Reviews Disease Primers</i> , 2019, 5, 74.	18.1	450
76	The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 171-189.	4.2	106
77	Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder. <i>Psychological Medicine</i> , 2019, 49, 1869-1878.	2.7	13
78	Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder. <i>Journal of Affective Disorders</i> , 2019, 246, 241-247.	2.0	50
79	Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 119-135.	1.0	116

#	ARTICLE	IF	CITATIONS
81	Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. <i>British Journal of Psychiatry</i> , 2019, 214, 27-35.	1.7	54
82	Lack of rapid antidepressant effects of Kir4.1 channel inhibitors in a chronic social defeat stress model: Comparison with (R)-ketamine. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 176, 57-62.	1.3	15
83	Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 213-236.	4.2	98
84	Ketamine in the Treatment of Depressive Episodes. <i>Pharmacopsychiatry</i> , 2020, 53, 45-50.	1.7	12
85	Ketamine as augmentation for the treatment of major depression and suicidal risk in advanced cancer: Case report. <i>Palliative and Supportive Care</i> , 2020, 18, 110-112.	0.6	8
86	Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial. <i>Depression and Anxiety</i> , 2020, 37, 224-233.	2.0	50
87	Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series. <i>Journal of Affective Disorders</i> , 2020, 262, 40-42.	2.0	4
88	Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies. <i>Journal of Affective Disorders</i> , 2020, 265, 63-70.	2.0	68
89	Targeted sequencing of the LRRTM gene family in suicide attempters with bipolar disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2020, 183, 128-139.	1.1	6
90	Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 29-45.	1.3	126
91	Symptom trajectories in the months before and after a suicide attempt in individuals with bipolar disorder: A STEP-BD study. <i>Bipolar Disorders</i> , 2020, 22, 245-254.	1.1	7
92	Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 188, 172837.	1.3	113
93	Ketamine and esketamine for suicidal ideation: Recent progress and practical issues. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 206-207.	1.3	4
94	Esketamine: A Novel Option for Treatment-Resistant Depression. <i>Annals of Pharmacotherapy</i> , 2020, 54, 567-576.	0.9	40
95	Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 354-363.	1.1	12
96	Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. <i>Neuropsychopharmacology</i> , 2020, 45, 606-612.	2.8	68
97	Neurobiological research with suicidal participants: A framework for investigators. <i>General Hospital Psychiatry</i> , 2020, 62, 43-48.	1.2	7
98	Dissociating the Clinical Role and Economic Value of Intranasal Esketamine. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2020, 26, 20-22.	0.5	2

#	ARTICLE	IF	CITATIONS
99	Glutamine and New Pharmacological Targets to Treat Suicidal Ideation. <i>Current Topics in Behavioral Neurosciences</i> , 2020, 46, 179-196.	0.8	8
101	Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Affective Disorders</i> , 2020, 276, 570-575.	2.0	30
102	Bipolar depression: a major unsolved challenge. <i>International Journal of Bipolar Disorders</i> , 2020, 8, 1.	0.8	137
103	Outpatient hospital ketamine: review of a growing trend in patient care. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 183-189.	0.4	9
104	Elucidating the chronic, complex nature of suicidal ideation: A national qualitative study of veterans with a recent suicide attempt. <i>Journal of Affective Disorders Reports</i> , 2020, 2, 100030.	0.9	2
105	&lt;p&gt;Ketamine in Bipolar Disorder: A Review&lt;/p&gt;. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 2707-2717.	1.0	22
106	Association between plasma levels of BDNF and the antisuicidal effects of repeated ketamine infusions in depression with suicidal ideation. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532097379.	1.2	7
107	Effects of ketamine in electroconvulsive therapy for major depressive disorder: meta-analysis of randomised controlled trials. <i>Annals of General Psychiatry</i> , 2020, 33, e100117.	1.1	6
108	Sustained Improvement of Negative Self-Schema After a Single Ketamine Infusion: An Open-Label Study. <i>Frontiers in Neuroscience</i> , 2020, 14, 687.	1.4	9
109	Telehealth and indigenous populations around the world: a systematic review on current modalities for physical and mental health. <i>MHealth</i> , 2020, 6, 30-30.	0.9	29
110	Predicting therapeutic response to oral ketamine for chronic suicidal ideation: a Bayesian network for clinical decision support. <i>BMC Psychiatry</i> , 2020, 20, 519.	1.1	9
111	Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7951.	1.8	18
112	Prognosis and Improved Outcomes in Major Depression: A Review. <i>Focus (American Psychiatric)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 20	0.4	21
113	Treatments for Self-Injurious Thoughts and Behaviors in Youth: Progress and Challenges. <i>Evidence-Based Practice in Child and Adolescent Mental Health</i> , 2020, 5, 354-364.	0.7	8
114	The Role of Opiates in Social Pain and Suicidal Behavior. <i>Current Topics in Behavioral Neurosciences</i> , 2020, 46, 197-210.	0.8	10
115	Adaptation of evidence-based suicide prevention strategies during and after the COVID-19 pandemic. <i>World Psychiatry</i> , 2020, 19, 294-306.	4.8	200
116	Interventions for self-harm in children and adolescents. <i>The Cochrane Library</i> , 0, , .	1.5	2
117	Pharmacological interventions for self-harm in adults. <i>The Cochrane Library</i> , 0, , .	1.5	3

#	ARTICLE	IF	CITATIONS
118	Magnetic Seizure Therapy for Suicidality in Treatment-Resistant Depression. JAMA Network Open, 2020, 3, e207434.	2.8	13
119	Fetal growth restriction mice are more likely to exhibit depression-like behaviors due to stress-induced loss of dopaminergic neurons in the VTA. FASEB Journal, 2020, 34, 13257-13271.	0.2	1
120	Intraoperative ketamine for reduction in postpartum depressive symptoms after cesarean delivery: A double-blind, randomized clinical trial. Brain and Behavior, 2020, 10, e01715.	1.0	28
121	Prehospital Analgesia and Sedation: a Perspective from the Battlefield. Current Trauma Reports, 2020, 6, 207-217.	0.6	1
122	Involvement of NMDA receptors containing the GluN2C subunit in the psychotomimetic and antidepressant-like effects of ketamine. Translational Psychiatry, 2020, 10, 427.	2.4	13
123	Network Changes in Insula and Amygdala Connectivity Accompany Implicit Suicidal Associations. Frontiers in Psychiatry, 2020, 11, 577628.	1.3	10
124	Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. Journal of Affective Disorders, 2020, 277, 478-485.	2.0	4
125	Ketamine-Magnesium for Refractory Chronic Cluster Headache: A Case Series. Headache, 2020, 60, 2537-2543.	1.8	8
126	Reply to Hashimoto: Ketamine is not an opioid but requires opioid system for antidepressant actions. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11202-11203.	3.3	2
127	Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 2020, 271, 228-238.	2.0	16
128	The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. Journal of Affective Disorders, 2020, 274, 903-910.	2.0	70
129	Ketamine for depression clinical issues. Advances in Pharmacology, 2020, 89, 131-162.	1.2	20
130	Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. Expert Opinion on Drug Safety, 2020, 19, 1031-1040.	1.0	25
131	What ketamine can teach us about the opioid system in depression?. Expert Opinion on Drug Discovery, 2020, 15, 1369-1372.	2.5	5
133	New Directions in Psychiatry. , 2020, , .		0
135	Adjunctive Vagus Nerve Stimulation for Treatment-Resistant Depression: a Quantitative Analysis. Psychiatric Quarterly, 2020, 91, 669-679.	1.1	9
136	Encoding, Consolidation, and Renormalization in Depression: Synaptic Homeostasis, Plasticity, and Sleep Integrate Rapid Antidepressant Effects. Pharmacological Reviews, 2020, 72, 439-465.	7.1	28
137	Reviewing the Potential of Psychedelics for the Treatment of PTSD. International Journal of Neuropsychopharmacology, 2020, 23, 385-400.	1.0	106



#	ARTICLE	IF	CITATIONS
138	Sedative and physiological effects of alfaxalone intramuscular administration in cynomolgus monkeys (&lt;i>Macaca fascicularis&lt;/i>). <i>Journal of Veterinary Medical Science</i> , 2020, 82, 1021-1029.	0.3	5
139	Interaction between Mesocortical and Mesothalamic Catecholaminergic Transmissions Associated with NMDA Receptor in the Locus Coeruleus. <i>Biomolecules</i> , 2020, 10, 990.	1.8	11
140	Subanesthetic ketamine exerts antidepressant-like effects in adult rats exposed to juvenile stress. <i>Brain Research</i> , 2020, 1746, 146980.	1.1	4
141	Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence. <i>Advances in Pharmacology</i> , 2020, 89, 163-194.	1.2	8
142	The emergence of ketamine as a novel treatment for posttraumatic stress disorder. <i>Advances in Pharmacology</i> , 2020, 89, 261-286.	1.2	48
143	A historical review of antidepressant effects of ketamine and its enantiomers. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 190, 172870.	1.3	109
144	Prioritizing suicide prevention guideline recommendations in specialist mental healthcare: a Delphi study. <i>BMC Psychiatry</i> , 2020, 20, 55.	1.1	15
145	Essential role of microglial transforming growth factor- $\beta$ 1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF- $\beta$ 1. <i>Translational Psychiatry</i> , 2020, 10, 32.	2.4	75
146	Predictors of response to repeated ketamine infusions in depression with suicidal ideation: An ROC curve analysis. <i>Journal of Affective Disorders</i> , 2020, 264, 263-271.	2.0	15
147	Suicide epigenetics, a review of recent progress. <i>Journal of Affective Disorders</i> , 2020, 265, 423-438.	2.0	21
148	Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients. <i>Journal of Psychiatric Research</i> , 2020, 123, 1-8.	1.5	41
149	Bipolar Disorder and Suicide: a Review. <i>Current Psychiatry Reports</i> , 2020, 22, 6.	2.1	185
150	Pharmacological Treatment of Major Depressive Disorder. , 2020, , 103-119.		2
151	All Suicidal Ideation Is Not Created Equal: Two Cases of Suicide Attempts During Maintenance Ketamine Treatment. <i>American Journal of Psychiatry</i> , 2020, 177, 173-174.	4.0	8
152	Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. <i>Biochemical Pharmacology</i> , 2020, 177, 113935.	2.0	135
153	Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. <i>Revue Neurologique</i> , 2020, 176, 325-352.	0.6	184
154	Altered anterior cingulate glutamatergic metabolism in depressed adolescents with current suicidal ideation. <i>Translational Psychiatry</i> , 2020, 10, 119.	2.4	33
155	Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. <i>Pharmacological Reports</i> , 2020, 72, 543-562.	1.5	82

#	ARTICLE	IF	CITATIONS
156	Registered clinical trials investigating ketamine for psychiatric disorders. <i>Journal of Psychiatric Research</i> , 2020, 127, 1-12.	1.5	22
157	A Review of Nonanesthetic Uses of Ketamine. <i>Anesthesiology Research and Practice</i> , 2020, 2020, 1-15.	0.2	38
158	Brain entropy and neurotrophic molecular markers accompanying clinical improvement after ketamine: Preliminary evidence in adolescents with treatment-resistant depression. <i>Journal of Psychopharmacology</i> , 2021, 35, 168-177.	2.0	15
159	Is ketamine a litmus test for capacity in assisted dying with depression?. <i>Psycho-Oncology</i> , 2021, 30, 417-420.	1.0	3
160	Ketamine: A tale of two enantiomers. <i>Journal of Psychopharmacology</i> , 2021, 35, 109-123.	2.0	101
161	Treatment Refractory Internalizing Behaviour Across Disorders: An Aetiological Model for Severe Emotion Dysregulation in Adolescence. <i>Child Psychiatry and Human Development</i> , 2021, 52, 515-532.	1.1	4
162	Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Psychiatric Research</i> , 2021, 136, 444-451.	1.5	1
163	Increased use of ketamine for the treatment of depression: Benefits and concerns. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110060.	2.5	11
164	Association between anhedonia and suicidal events in patients with mood disorders: A 3-year prospective study. <i>Depression and Anxiety</i> , 2021, 38, 17-27.	2.0	25
165	Advances in novel molecular targets for antidepressants. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110041.	2.5	11
166	Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2021, 278, 542-555.	2.0	193
167	Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 105, 110126.	2.5	12
168	Intermittent repeated stress but not ketamine changes mice response to antidepressants. <i>Neuroscience Letters</i> , 2021, 741, 135452.	1.0	4
169	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommendations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Ketamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 113-125.	1.0	54
170	The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2021, 134, 57-68.	1.5	58
171	Subanesthetic dose of ketamine for the antidepressant effects and the associated cognitive impairments of electroconvulsive therapy in elderly patients: A randomized, double-blind, controlled clinical study. <i>Brain and Behavior</i> , 2021, 11, e01775.	1.0	12
172	Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences. <i>BJPsych Open</i> , 2021, 7, e9.	0.3	7
173	Ketamine and Esketamine augmentation for suicidal ideation: A randomized, double-blinded clinical trial. <i>General Hospital Psychiatry</i> , 2021, 68, 97-99.	1.2	16

#	ARTICLE	IF	CITATIONS
174	Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression. <i>Psychiatry Research</i> , 2021, 296, 113645.	1.7	4
175	Esketamine for Postpartum Suicidality. <i>Biological Psychiatry</i> , 2021, 89, e35-e36.	0.7	2
176	Biological bases of suicidal behaviours: A narrative review. <i>European Journal of Neuroscience</i> , 2021, 53, 330-351.	1.2	37
177	Novel therapeutic drug targets for bipolar disorder. , 2021, , 393-404.		0
178	Suicide in psychiatry and medical liability: A case series. <i>International Journal of Law and Psychiatry</i> , 2021, 74, 101671.	0.5	1
179	Suicide and Suicide Attempts During Adolescence. , 2021, , .		1
180	Association of plasma VEGF levels and the antidepressant effects of ketamine in patients with depression. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110143.	1.2	5
181	“Novel Psychopharmacology for Depressive Disorders” <i>Advances in Experimental Medicine and Biology</i> , 2021, 1305, 449-461.	0.8	12
182	Pharmacological interventions for self-harm in adults. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	7
183	New Methods for Assessing Rapid Changes in Suicide Risk. <i>Frontiers in Psychiatry</i> , 2021, 12, 598434.	1.3	31
184	Linking 5-hydroxytryptamine to antidepressant actions of (R)-ketamine and social stress model. , 2021, , 393-399.		0
185	Clinical effect of low-dose ketamine in early postoperative period after caesarean section (meta-analysis). <i>Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya I Reanimatologiya</i> , 2021, , 19.	0.2	0
186	Overview of ketamine for major depression: efficacy and effectiveness. , 2021, , 117-129.		2
187	Suicide as a Systemic Disorder. , 2021, , 321-333.		0
188	Sedation in the Emergency Department: A Complex and Multifactorial Challenge. , 2021, , 413-473.		0
189	Ketamine for depression. <i>International Review of Psychiatry</i> , 2021, 33, 207-228.	1.4	30
190	Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective?. <i>Frontiers in Behavioral Neuroscience</i> , 2021, 15, 626906.	1.0	60
191	Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study. <i>Translational Psychiatry</i> , 2021, 11, 101.	2.4	31

#	ARTICLE	IF	CITATIONS
192	Clinical trials for rapid changes in suicidal ideation: Lessons from ketamine. <i>Suicide and Life-Threatening Behavior</i> , 2021, 51, 27-35.	0.9	5
193	Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial. <i>Archives of Suicide Research</i> , 2022, 26, 1250-1265.	1.2	10
194	Suicide prevention in psychiatric patients. <i>Asia-Pacific Psychiatry</i> , 2021, 13, e12450.	1.2	21
195	Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 553-562.	2.5	64
196	A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. <i>Journal of Affective Disorders</i> , 2021, 282, 160-164.	2.0	24
197	An Update on the Latest Treatment Approaches with Suicidal Adolescents. <i>Current Treatment Options in Psychiatry</i> , 2021, 8, 64-76.	0.7	2
198	Bipolar Affective Disorder in Men. , 2021, , 147-158.		1
199	Interventions for self-harm in children and adolescents. <i>The Cochrane Library</i> , 2021, 2021, CD013667.	1.5	42
200	Meta-Analysis: Hemodynamic Responses to Sub-anesthetic Doses of Ketamine in Patients With Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2021, 12, 549080.	1.3	9
201	Immediate and short-term efficacy of suicide-targeted interventions in suicidal individuals: A systematic review. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 670-685.	1.3	8
202	Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. <i>CNS Drugs</i> , 2021, 35, 527-543.	2.7	74
203	Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?. <i>Frontiers in Neuroscience</i> , 2021, 15, 657714.	1.4	13
204	Ketamine for Bipolar Depression: A Systematic Review. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 535-541.	1.0	20
205	Psilocybin and MDMA for the treatment of trauma-related psychopathology. <i>International Review of Psychiatry</i> , 2021, 33, 229-249.	1.4	46
206	Cerebrospinal fluid levels of monoamines among suicide attempters: A systematic review and random-effects meta-analysis. <i>Journal of Psychiatric Research</i> , 2021, 136, 224-235.	1.5	11
207	Intranasal esketamine: From origins to future implications in treatment-resistant depression. <i>Journal of Psychiatric Research</i> , 2021, 137, 29-35.	1.5	17
208	Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review. <i>Journal of Psychiatric Research</i> , 2021, 137, 426-436.	1.5	27
209	Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action. <i>Mental Health Clinician</i> , 2021, 11, 200-210.	0.5	2

#	ARTICLE	IF	CITATIONS
210	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021, 178, 383-399.	4.0	270
211	Ketamine for acute suicidality in the emergency department: A systematic review. <i>American Journal of Emergency Medicine</i> , 2021, 43, 54-58.	0.7	4
212	Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. <i>Molecular Psychiatry</i> , 2022, 27, 559-573.	4.1	122
213	Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review. <i>Journal of Psychopharmacology</i> , 2021, 35, 934-945.	2.0	39
214	Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature. <i>Brain Sciences</i> , 2021, 11, 856.	1.1	42
215	Neuroinflammation and the Kynurenine Pathway in CNS Disease: Molecular Mechanisms and Therapeutic Implications. <i>Cells</i> , 2021, 10, 1548.	1.8	69
216	Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 83-94.	1.0	12
217	Ketamine: Safe and Effective Treatment for Severe Depression. <i>Journal of the American Psychiatric Nurses Association</i> , 2021, 27, 107839032110330.	0.4	0
218	S-ketamine alleviates carbon tetrachloride-induced hepatic injury and oxidative stress by targeting the Nrf2/HO-1 signaling pathway. <i>Canadian Journal of Physiology and Pharmacology</i> , 2021, 99, 1308-1315.	0.7	7
219	Combining Ketamine and Internet-Based Cognitive Behavioral Therapy for the Treatment of Posttraumatic Stress Disorder: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2021, 10, e30334.	0.5	4
220	Online news media reporting of ketamine as a treatment for depression from 2000 to 2017. <i>Irish Journal of Psychological Medicine</i> , 2023, 40, 607-615.	0.7	5
221	Ketamine in depression and electroconvulsive therapy. <i>Current Opinion in Anaesthesiology</i> , 2021, 34, 556-562.	0.9	5
222	Structural basis of ketamine action on human NMDA receptors. <i>Nature</i> , 2021, 596, 301-305.	18.7	76
223	Key considerations in the pharmacological management of treatment-resistant depression. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2405-2415.	0.9	3
224	Characteristics and treatment outcome of suicidal depression: Two large naturalistic cohorts of depressed outpatients. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 347-364.	1.3	11
225	Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study. <i>CNS Drugs</i> , 2021, 35, 881-892.	2.7	10
226	Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2637-2646.	1.0	19
227	Gut microbiota is involved in the antidepressant-like effect of (S)-norketamine in an inflammation model of depression. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 207, 173226.	1.3	18

#	ARTICLE	IF	CITATIONS
228	The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE). <i>Psychiatry Research</i> , 2021, 302, 113993.	1.7	16
229	The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. <i>European Neuropsychopharmacology</i> , 2021, 49, 122-132.	0.3	17
230	Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk. <i>CNS Drugs</i> , 2021, 35, 1069-1079.	2.7	9
231	Emergence of Ketamine as a Rapid Acting Antidepressant: Mechanistic Insights and Future Directions. , 0, , .		0
232	Novel antidepressant drugs: Beyond monoamine targets. <i>CNS Spectrums</i> , 2023, 28, 6-15.	0.7	19
233	Dysfunction of default mode network is associated with active suicidal ideation in youths and young adults with depression: Findings from the T-RAD study. <i>Journal of Psychiatric Research</i> , 2021, 142, 258-262.	1.5	10
234	Severe Encephalatrophy and Related Disorders From Long-Term Ketamine Abuse: A Case Report and Literature Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 707326.	1.3	4
235	Glutamate levels in the medial prefrontal cortex of healthy pregnant women compared to non-pregnant controls. <i>Psychoneuroendocrinology</i> , 2021, 133, 105382.	1.3	3
236	Six-week oral ketamine treatment for chronic suicidality is associated with increased grey matter volume. <i>Psychiatry Research - Neuroimaging</i> , 2021, 317, 111369.	0.9	11
237	Recent advances and challenges in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110403.	2.5	2
238	The effect of ketamine on preventing postpartum depression. <i>Journal of Medicine and Life</i> , 2021, 14, 87-92.	0.4	18
239	Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 431-438.	1.8	17
240	Antidepressant Actions of Ketamine and Its Two Enantiomers. , 2020, , 105-125.		2
241	Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation. <i>CNS Spectrums</i> , 2022, 27, 315-321.	0.7	7
242	Reflections on Suicidal Ideation. <i>Crisis</i> , 2019, 40, 227-230.	0.9	133
243	Effects of cannabinoid administration for pain: A meta-analysis and meta-regression.. <i>Experimental and Clinical Psychopharmacology</i> , 2019, 27, 370-382.	1.3	34
244	The role of dissociation in ketamine's antidepressant effects. <i>Nature Communications</i> , 2020, 11, 6431.	5.8	89
245	Ketamine and Monoamine Oxidase Inhibitor Combination. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 636-638.	0.7	11

#	ARTICLE	IF	CITATIONS
246	Annual Research Review: Defining and treating pediatric treatment-resistant depression. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2020, 61, 312-332.	3.1	51
247	Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532091665.	1.2	95
249	Ketamine for chronic depression: two cautionary tales. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 384-385.	1.4	9
250	Brazilian Psychiatric Association guidelines for the management of suicidal behavior. Part 2. Screening, intervention, and prevention. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 538-549.	0.9	11
251	Rapid-Acting Antidepressants. <i>Current Pharmaceutical Design</i> , 2018, 24, 2556-2563.	0.9	36
252	Development of Ketamine Administration as a Treatment for Chronic PTSD. <i>Psychiatric Annals</i> , 2020, 50, 68-76.	0.1	2
253	Not So Fast. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	6
254	Antidepressant efficacy and side effect burden: an updated guide for clinicians. <i>Drugs in Context</i> , 2020, 9, 1-11.	1.0	10
255	Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 553-561.	0.7	7
256	Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 704330.	1.3	19
257	The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality. <i>Journal of Psychiatric Research</i> , 2021, 144, 312-319.	1.5	9
258	Effects of somatic treatments on suicidal ideation and completed suicides. <i>Brain and Behavior</i> , 2021, 11, e2381.	1.0	11
259	Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. <i>Human Psychopharmacology</i> , 2022, 37, e2820.	0.7	2
260	Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics. <i>Current Treatment Options in Psychiatry</i> , 2021, 8, 229-257.	0.7	1
262	Ketamine as a Rapid Antidepressant. , 2019, , 139-145.		2
264	Antidepressiva. , 2019, , 1-208.		4
265	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. , 2019, , 1-119.		0
267	Clinical Trials With Suicidal Individuals Can Be Conducted Safely. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	2

#	ARTICLE	IF	CITATIONS
268	Treatment options for pharmacoresistant depression in routine clinical practice. <i>Psychiatrie Pro Praxi</i> , 2020, 21, 124-127.	0.0	0
269	Effects of Discontinuation of Drugs Used for Augmentation Therapy on Treatment Outcomes in Depression: A Systematic Review and Meta-analysis. <i>Pharmacopsychiatry</i> , 2021, 54, 106-116.	1.7	1
270	The next psychoactive drugs: From imipramine to ketamine. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2020, 204, e169-e177.	0.0	0
271	Affective Disorders. , 2021, , .		0
272	Ketamine Normalizes the Structural Alterations of Inferior Frontal Gyrus in Depression. <i>Chronic Stress</i> , 2020, 4, 247054702098068.	1.7	18
273	Synaptic Modulation in the Effect of Ketamine. , 2020, , 69-87.		1
274	Unipolar depression. , 2020, , 613-631.		0
275	Effects of Adjunctive Ketamine Intravenous Infusion in Taiwanese Patients with Treatment-Resistant Depression: Antidepressant, Antisuicidality, BDNF Val66Met, and Brain Imaging. , 2020, , 175-189.		0
276	Unmet Needs in Psychiatry: Bipolar Depression. , 2020, , 39-82.		2
277	Ketamine, Esketamine, and A New Generation of Antidepressants. <i>Psychiatric Annals</i> , 2020, 50, 54-61.	0.1	0
278	Neurobiological Mechanisms of Ketamine: Depression, Suicide, Trauma, and Chronic Stress Pathologies. <i>Psychiatric Annals</i> , 2020, 50, 48-53.	0.1	6
279	Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. , 2021, 33, e10-e20.		8
280	High-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) Accelerates onset Time of Beneficial Treating Effects and Improves Clinical Symptoms of Depression. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022, 21, 500-510.	0.8	4
281	Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials. <i>Journal of Psychiatric Research</i> , 2021, 144, 448-454.	1.5	3
282	Rapid-Acting Antidepressants: Mechanistic Insights and Future Directions. <i>Current Behavioral Neuroscience Reports</i> , 2018, 5, 36-47.	0.6	16
283	An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis. <i>Psychopharmacology Bulletin</i> , 2020, 50, 137-163.	0.0	2
284	A study on the effects of mindfulness-based cognitive therapy and loving-kindness meditation on depression, rumination, mindfulness level and quality of life in depressed patients. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 4666-4675.	0.0	3
285	Treatment Approaches with Suicidal Adolescents. , 2021, , 1-22.		1



#	ARTICLE	IF	CITATIONS
286	Hallucinogen-Related Disorders. <i>Psychiatry Update</i> , 2022, , 41-56.	0.1	0
287	Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. <i>Molecular Psychiatry</i> , 2022, 27, 1618-1629.	4.1	87
288	An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 710338.	1.3	17
289	“Ketamine for non-suicidal self-harm in borderline personality disorder with co-morbid recurrent depression: A case report” <i>Journal of Affective Disorders Reports</i> , 2021, 6, 100280.	0.9	2
290	Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 780975.	1.3	6
291	Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency. <i>Brain, Behavior, &amp; Immunity - Health</i> , 2021, 18, 100383.	1.3	22
292	Ketamine for treatment-resistant depression. <i>Mustansiriya Medical Journal</i> , 2021, 20, 27.	0.1	0
293	CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity. <i>Neuropharmacology</i> , 2022, 206, 108936.	2.0	6
294	Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 115, 110507.	2.5	10
295	mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2022, 303, 91-97.	2.0	22
296	N-Acetylcysteine as a novel rapidly acting anti-suicidal agent: A pilot naturalistic study in the emergency setting. <i>PLoS ONE</i> , 2022, 17, e0263149.	1.1	5
297	Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 715-718.	1.3	6
299	Ketamine for suicidal ideation. <i>BMJ</i> , The, 0, , o74.	3.0	0
300	Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. <i>BMJ</i> , The, 2022, 376, e067194.	3.0	47
301	Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120152.	0.3	11
303	Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. <i>BJPsych Open</i> , 2022, 8, e19.	0.3	45
304	A systematic review of studies investigating the acute effects of N-methyl-D-aspartate receptor antagonists on behavioural despair in normal animals suggests poor predictive validity. <i>Brain and Neuroscience Advances</i> , 2022, 6, 239821282210816.	1.8	8
305	A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers With PTSD and Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 803279.	1.3	12

#	ARTICLE	IF	CITATIONS
307	Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. <i>CNS Drugs</i> , 2022, 36, 239-251.	2.7	8
308	Can ketamine be a safe option for treatment-resistant bipolar depression?. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 717-720.	1.0	9
309	S-ketamine as an adjuvant in patient-controlled intravenous analgesia for preventing postpartum depression: a randomized controlled trial. <i>BMC Anesthesiology</i> , 2022, 22, 49.	0.7	41
311	A Computational Model of Hopelessness and Active-Escape Bias in Suicidality. <i>Computational Psychiatry</i> , 2022, 6, 34.	1.1	5
312	Genetics and Brain Transcriptomics of Completed Suicide. <i>American Journal of Psychiatry</i> , 2022, 179, 226-241.	4.0	17
313	Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions. <i>Brain Sciences</i> , 2022, 12, 382.	1.1	13
314	Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 853-866.	1.0	24
315	A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 745-759.	1.0	1
316	Pre-treatment Pain Symptoms Influence Antidepressant Response to Ketamine in Depressive Patients. <i>Frontiers in Psychiatry</i> , 2022, 13, 793677.	1.3	2
317	The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review. <i>Cureus</i> , 2022, 14, e23647.	0.2	0
318	Optimized Clinical Strategies for Treatment-Resistant Depression: Integrating Ketamine Protocols with Trauma- and Attachment-Informed Psychotherapy. <i>Psych</i> , 2022, 4, 119-141.	0.7	4
319	Mechanisms of the Rapid Effects of Ketamine on Depression and Sleep Disturbances: A Narrative Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 782457.	1.6	12
320	Repetitive Transcranial Magnetic Stimulation Promotes Rapid Psychiatric Stabilization in Acutely Suicidal Military Service Members. <i>Journal of ECT</i> , 2022, 38, 103-109.	0.3	2
322	Suicide Risk in Youth and Young Adults with Type 1 Diabetes: a Review of the Literature and Clinical Recommendations for Prevention. <i>Current Diabetes Reports</i> , 2021, 21, 51.	1.7	6
323	Anhedonia and Suicide. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 443-464.	0.8	8
324	Characterization of suicidal depression: A 1 year prospective study. <i>European Psychiatry</i> , 2022, 65, 1-40.	0.1	6
325	Ketamine treatment for depression: a review. <i>Discover Mental Health</i> , 2022, 2, 9.	1.0	37
326	Prospective association of psychological pain and hopelessness with suicidal thoughts. <i>Journal of Affective Disorders</i> , 2022, 308, 243-248.	2.0	8

#	ARTICLE	IF	CITATIONS
329	Ketamine for suicidality: An umbrella review. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3990-4018.	1.1	4
330	Pharmacological Treatments for Anhedonia. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 467-489.	0.8	4
331	Plasma VEGF Concentrations and Ketamine's Effects on Suicidal Ideation in Depression With Suicidal Ideation. <i>Frontiers in Psychiatry</i> , 2022, 13, 855995.	1.3	4
332	Intravenous Ketamine as a Treatment Option for Patients Presenting to the ED With Suicidal Ideation. <i>The American Journal of Psychiatry Residents' Journal</i> , 2022, 17, 4-6.	0.2	0
333	Craving and addictive potential of esketamine as side effects?. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 803-812.	1.0	3
334	Dopamine Function and Hypothalamic-Pituitary-Thyroid Axis Activity in Major Depressed Patients with Suicidal Behavior. <i>Brain Sciences</i> , 2022, 12, 621.	1.1	7
335	Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation. , 2022, 239, 108195.		20
336	Early improvement as a predictor of final remission in patients with treatment-resistant depression receiving electroconvulsive therapy with ketofol anesthesia. <i>Journal of Affective Disorders</i> , 2022, 310, 223-227.	2.0	2
337	Efficacy and Tolerability of Two Novel "Standard of Care" Treatments" Intranasal Esketamine Versus Intravenous Ketamine" for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study. <i>JMIR Research Protocols</i> , 2022, 11, e34711.	0.5	1
338	Risk of Suicidal Behaviors and Antidepressant Exposure Among Children and Adolescents: A Meta-Analysis of Observational Studies. <i>Frontiers in Psychiatry</i> , 2022, 13, .	1.3	14
339	Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression. <i>Journal of Affective Disorders</i> , 2022, 312, 188-197.	2.0	3
340	Novel uses of ketamine in the emergency department. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 1009-1025.	1.0	4
341	Toward a Better Understanding of the Mechanisms and Pathophysiology of Anhedonia: Are We Ready for Translation?. <i>American Journal of Psychiatry</i> , 2022, 179, 458-469.	4.0	41
342	Inibidores da monoaminoxidase e cetamina intravenosa: uma associa�o segura?. <i>Revista Debates Em Psiquiatria</i> , 0, 12, 1-20.	0.3	0
343	(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 139, 104762.	2.9	17
344	Managing Suicide Ideation: A Targeted Approach. <i>Annals of the Academy of Medicine, Singapore</i> , 2019, 48, 279-281.	0.2	0
345	The molecular pathophysiology of depression and the new therapeutics. <i>MedComm</i> , 2022, 3, .	3.1	20
346	Higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users. <i>Journal of Psychiatry and Neuroscience</i> , 2022, 47, E263-E271.	1.4	1

#	ARTICLE	IF	CITATIONS
347	Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies. <i>Psychiatry Research</i> , 2022, 316, 114749.	1.7	2
348	A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 827-838.	1.0	4
349	Bipolar depression: a review of treatment options. <i>Annals of General Psychiatry</i> , 2022, 35, e100760.	1.1	18
351	The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder. <i>Journal of Affective Disorders</i> , 2022, 315, 13-16.	2.0	3
352	A bibliometric analysis of research on (R)-ketamine from 2002 to 2021. <i>Neuropharmacology</i> , 2022, 218, 109207.	2.0	19
353	Arketamine, a new rapid-acting antidepressant: A historical review and future directions. <i>Neuropharmacology</i> , 2022, 218, 109219.	2.0	41
354	Targeting NMDA Receptors at the Neurovascular Unit: Past and Future Treatments for Central Nervous System Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10336.	1.8	16
355	Depression and antidepressant effects of ketamine and its metabolites: The pivotal role of gut microbiota. <i>Neuropharmacology</i> , 2022, 220, 109272.	2.0	17
356	Dreaming and psychiatric disorders. , 2023, , 199-207.		0
357	Coming clean: Saying "I know" to drugs " Part I. <i>South African General Practitioner</i> , 2022, 3, 55-58.	0.0	0
358	Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression. <i>Clinical Drug Investigation</i> , 2022, 42, 865-873.	1.1	8
359	Plasticity of synapses and reward circuit function in the genesis and treatment of depression. <i>Neuropsychopharmacology</i> , 2023, 48, 90-103.	2.8	8
360	Psychiatric Treatment and Repeat Suicide Attempts Among Adults With Substance Use, by HIV Status, United States, 2014-2020. <i>Public Health Reports</i> , 0, , 003335492211204.	1.3	0
361	Association of intranasal esketamine, a novel "standard of care" treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice. <i>BMJ Open</i> , 2022, 12, e060967.	0.8	3
362	Gender differences in the antianhedonic effects of repeated ketamine infusions in patients with depression. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
363	Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	5
364	A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs. <i>European Neuropsychopharmacology</i> , 2022, 64, 44-60.	0.3	13
365	(Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy. <i>Chronic Stress</i> , 2022, 6, 247054702211280.	1.7	4

#	ARTICLE	IF	CITATIONS
366	Alteration in NMDAR subunits in different brain regions of chronic unpredictable mild stress (CUMS) rat model. <i>Translational Neuroscience</i> , 2022, 13, 379-389.	0.7	1
367	Resolution of depression: Antidepressant actions of resolvins. <i>Neuroscience Research</i> , 2022, , .	1.0	5
368	Inpatient suicide in psychiatric settings: Evaluation of current prevention measures. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
369	The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier?. <i>Cureus</i> , 2022, , .	0.2	2
370	Ketamine and its metabolites: Potential as novel treatments for depression. <i>Neuropharmacology</i> , 2023, 222, 109305.	2.0	31
371	Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions. <i>International Journal of Psychiatry in Clinical Practice</i> , 2023, 27, 145-150.	1.2	1
372	Efficacy of ketamine for comorbid depression and acute or chronic pain: A systematic review. <i>Frontiers in Pain Research</i> , 0, 3, .	0.9	4
373	Microdosing with classical psychedelics: Research trajectories and practical considerations. <i>Transcultural Psychiatry</i> , 0, , 136346152211291.	0.9	3
374	Retrospective data analysis to determine the effectiveness of intravenous ketamine therapy on patients suffering from depression with suicidal ideation. <i>Industrial Psychiatry</i> , 2023, 32, 86.	0.3	0
375	Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine. <i>Neuropharmacology</i> , 2023, 224, 109335.	2.0	16
377	Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2023, 323, 534-539.	2.0	4
378	NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research. <i>Neuropharmacology</i> , 2023, 225, 109378.	2.0	10
379	Treatment Approaches with Suicidal Adolescents. , 2022, , 421-442.		0
380	The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	6
381	Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2023, 8, 361-386.	1.1	3
382	An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression. <i>American Journal of Psychiatry</i> , 2022, 179, 890-891.	4.0	1
383	The Incidental Resolution of Severe Alcohol Use Disorder during Esketamine Treatment of Major Depressive Disorder: A Case Report. <i>Case Reports in Psychiatry</i> , 2022, 2022, 1-4.	0.2	0
384	Rapid-acting antidepressants targeting modulation of the glutamatergic system: clinical and preclinical evidence and mechanisms. <i>Annals of General Psychiatry</i> , 2022, 35, e100922.	1.1	5

#	ARTICLE	IF	CITATIONS
385	Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression. <i>Bipolar Disorders</i> , 2023, 25, 99-109.	1.1	18
386	Ketamine as a Treatment Option for Severe Borderline Personality Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2023, 43, 64-65.	0.7	0
387	Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial. <i>Journal of Affective Disorders</i> , 2023, 325, 127-134.	2.0	5
388	Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. <i>Neuropharmacology</i> , 2023, 226, 109422.	2.0	16
389	Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review. <i>Therapeutic Advances in Psychopharmacology</i> , 2023, 13, 204512532311513.	1.2	13
390	Changes in white matter microstructure following serial ketamine infusions in treatment resistant depression. <i>Human Brain Mapping</i> , 2023, 44, 2395-2406.	1.9	6
391	Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies. <i>Molecular Psychiatry</i> , 0, , .	4.1	13
392	Inflammation, stress and depression: An exploration of ketamine's therapeutic profile. <i>Drug Discovery Today</i> , 2023, 28, 103518.	3.2	14
393	Novel ketamine and zinc treatment for anorexia nervosa and the potential beneficial interactions with the gut microbiome. <i>Neuroscience and Biobehavioral Reviews</i> , 2023, 148, 105122.	2.9	1
394	Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	1
395	Traxoprodil Produces Antidepressant-Like Behaviors in Chronic Unpredictable Mild Stress Mice through BDNF/ERK/CREB and AKT/FOXO/Bim Signaling Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-19.	1.9	4
396	Arketamine for cognitive impairment in psychiatric disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 1513-1525.	1.8	16
397	New and emerging approaches to treat psychiatric disorders. <i>Nature Medicine</i> , 2023, 29, 317-333.	15.2	22
398	The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2023, 33, 20-26.	0.7	4
399	Intravenous ketamine for severe alcohol use disorder at Moi Teaching & Referral Hospital, Kenya: a case report. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2023, 18, .	1.0	1
400	Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions. <i>Pharmacology Biochemistry and Behavior</i> , 2023, 223, 173531.	1.3	4
401	Schnell-Wirksame Antidepressiva. , 2022, , 181-201.		0
402	The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence. <i>Therapeutic Advances in Psychopharmacology</i> , 2023, 13, 204512532311541.	1.2	19

#	ARTICLE	IF	CITATIONS
403	Pharmacotherapy. <i>Psychiatric Clinics of North America</i> , 2023, 46, 277-290.	0.7	2
404	Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 19, 587-599.	1.0	4
405	Understanding Suicide Among Military Service Members and Veterans: Risk and Protective Factors, Theory, and Intervention. , 2023, , 279-301.		0
406	Effect of a single dose of intravenous ketamine on the wish to hasten death in palliative care: A case report in advanced cancer. <i>Palliative and Supportive Care</i> , 2023, 21, 765-767.	0.6	1
407	A Pain Physician and Anesthesiologist's Perspective on Ketamine for Treatment-Resistant Depression. <i>SN Comprehensive Clinical Medicine</i> , 2023, 5, .	0.3	0
408	A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation. <i>International Journal of Neuropsychopharmacology</i> , 2023, 26, 331-339.	1.0	6
409	Pre-treatment functional connectivity of the cingulate cortex predicts anti-suicidal effects of serial ketamine infusions. <i>European Psychiatry</i> , 2023, 66, .	0.1	0
410	Ketamine as an alternative to ECT in catatonia in elderly women with bipolar disorder: A case report. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	0
411	Designing Clinical Trials to Assess the Impact of Pharmacological Treatment for Suicidal Ideation/Behavior: Issues and Potential Solutions. <i>Pharmaceutical Medicine</i> , 2023, 37, 221-232.	1.0	2
412	Psychopharmacology and Neuromodulation. , 2020, , .		0
427	No time to lose: the current state of research in rapid-acting psychotherapeutics. <i>Neuropsychopharmacology</i> , 0, , .	2.8	1
437	Editorial: Bridging the gap: an interdisciplinary perspective on ketamine in psychiatric disorders. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	0
452	Ketamine for Major Depressive Disorder. <i>Current Topics in Behavioral Neurosciences</i> , 2023, , .	0.8	0
466	Roles of the medial and lateral orbitofrontal cortex in major depression and its treatment. <i>Molecular Psychiatry</i> , 0, , .	4.1	0